• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Acidophil

edit

Acidophil, LLC is an innovation partnership whose goal is to create and develop technological solutions to areas of high unmet need. Acidophil’s eponymous founders are Nobel Prize winner Sydney Brenner MD, PhD, and Philip Goelet PhD. Acidophil’s team identifies unmet needs, develops or in-licenses enabling intellectual properties, recruits relevant experts, establishes proof of principle, develops commercial plans and participates in bringing its projects to completion through partnering with either corporations or venture capitalists. Current areas of interest include:

The application of biotechnology to the therapy and diagnosis of cancer, cardiovascular disease, and disorders of the central nervous system.

The application of biotechnology to renewable chemistry and environmental remediation.

Recent Milestones

edit

• 
  Acidophil invested in Corridor Pharmaceuticals. (6/16/10)
  Posted 7/8/10 at 7:56pm via yahoo.com
• 
  Acidophil invested in Arginetix. (11/2/09)
  Posted 11/2/09 at 9:01pm via onbiovc.com
• 
  Acidophil invested in Arginetix. (10/23/08)
  Posted 6/18/09 at 12:34am via findarticles.com
• 
  Acidophil added Philip Goelet PhD as President and co-founder of Acidophil.
  Posted 6/18/09 at 7:37am
• 
  Acidophil added Sydney Brenner MD PhD as co-founder of Acidophil.
  Posted 6/18/09 at 7:37am

Videos

Screenshots

edit

Sources

1. Arginetix and Immune Control Merge to Form Corridor Pharmaceuticals (finance.yahoo.com) [edit]
2. Arginetix, Inc.: Series B $4.6M (onbiovc.com) [edit]
3. Arginetix, Inc. Completes $2.3 Million Initial Financing and Technology License (findarticles.com) [edit]